UPDATE 1-Sinopharm offers to take China-TCM private in nearly $3 bln deal

Reuters02-21

(Updates with offer details and background)

Feb 21 (Reuters) - Sinopharm, the parent of China Traditional Chinese Medicine Holdings , has revived a take-private bid for the Hong-Kong-listed drugmaker, valuing it at HK$23.16 billion ($2.96 billion), the companies said on Wednesday.

China National Pharmaceutical, also known as Sinopharm, had in 2021 decided against a possible privatisation of China TCM.

The state-backed firm already holds a 32.46% stake in China-TCM and has offered to pay HK$4.6 per share in cash to buyout the drugmaker.

The offer price represents a 34.11% premium to the traditional medicine maker's closing price of HK$3.43 per share before trading in the stock was halted.

Sinopharm has also indicated it will not raise the offer price to take China-TCM private.

($1 = 7.8215 Hong Kong dollars)

(Reporting by Rishav Chatterjee in Bengalurul; Editing by Arun Koyyur)

((Rishav.Chatterjee@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2413182442?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-02-21 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2413182442","market":"hk","top_or_hot":-1,"title":"UPDATE 1-Sinopharm offers to take China-TCM private in nearly $3 bln deal","media":"Reuters","content":"<html><body><p>(Updates with offer details and background)</p><p>      Feb 21 (Reuters) - Sinopharm, the parent of China Traditional Chinese Medicine Holdings   , has revived a take-private bid for the Hong-Kong-listed drugmaker, valuing it at HK$23.16 billion ($2.96 billion), the companies said on Wednesday. </p><p>   China National Pharmaceutical, also known as Sinopharm, had in 2021 decided against a possible privatisation of China TCM. </p><p>   The state-backed firm already holds a 32.46% stake in China-TCM and has offered to pay HK$4.6 per share in cash to buyout the drugmaker.</p><p>   The offer price represents a 34.11% premium to the traditional medicine maker's closing price of HK$3.43 per share before trading in the stock was halted.</p><p>   Sinopharm has also indicated it will not raise the offer price to take China-TCM private.</p><p>($1 = 7.8215 Hong Kong dollars)</p><p> (Reporting by Rishav Chatterjee in Bengalurul; Editing by Arun Koyyur)</p><p>((Rishav.Chatterjee@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-Sinopharm offers to take China-TCM private in nearly $3 bln deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-Sinopharm offers to take China-TCM private in nearly $3 bln deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-21 20:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Updates with offer details and background)      Feb 21 (Reuters) - Sinopharm, the parent of China Traditional Chinese Medicine Holdings   , has revived a take-private bid for the Hong-Kong-listed ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00570","symbol_name":"中国中药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2413182442","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2413182442","pubTimestamp":1708519370,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"(Updates with offer details and background)      Feb 21 (Reuters) - Sinopharm, the parent of China Traditional Chinese Medicine Holdings   , has revived a take-private bid for the Hong-Kong-listed dru","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00570":"中国中药","BK1197":"保健护理产品经销商","01099":"国药控股","LU0640798160.USD":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","BK1606":"中医药概念","BK1500":"做空集合股","BK1515":"抗疫概念","BK1191":"制药","LU1115378108.SGD":"Eastspring Investments - Global Emerging Markets Dynamic AS SGD"},"translate_title":"最新消息1-国药控股提出以近30亿美元的价格将中国中药私有化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1,"00570":0.9},"content_text":"(Updates with offer details and background)      Feb 21 (Reuters) - Sinopharm, the parent of China Traditional Chinese Medicine Holdings   , has revived a take-private bid for the Hong-Kong-listed drugmaker, valuing it at HK$23.16 billion ($2.96 billion), the companies said on Wednesday.    China National Pharmaceutical, also known as Sinopharm, had in 2021 decided against a possible privatisation of China TCM.    The state-backed firm already holds a 32.46% stake in China-TCM and has offered to pay HK$4.6 per share in cash to buyout the drugmaker.   The offer price represents a 34.11% premium to the traditional medicine maker's closing price of HK$3.43 per share before trading in the stock was halted.   Sinopharm has also indicated it will not raise the offer price to take China-TCM private.($1 = 7.8215 Hong Kong dollars) (Reporting by Rishav Chatterjee in Bengalurul; Editing by Arun Koyyur)((Rishav.Chatterjee@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2413182442"}